Home
Publishing
DrugRxiv
Drug Repurposing
Network Medicine
About
REPO4EU
Meet the team
Drug Repurposing Research Collection
Conference
Blog
My ScienceOpen
Sign in
Register
Dashboard
Search
Home
Publishing
DrugRxiv
Drug Repurposing
Network Medicine
About
REPO4EU
Meet the team
Drug Repurposing Research Collection
Conference
My ScienceOpen
Sign in
Register
Dashboard
Search
31
views
0
references
Top references
cited by
1
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,671
similar
All similar
Record
: found
Abstract
: not found
Book
: not found
Arzneiverordnungs-Report 2016
other
Editor(s):
Ulrich Schwabe
,
Dieter Paffrath
Publication date
(Print):
2016
Publisher:
Springer Berlin Heidelberg
Read this book at
Publisher
Buy book
Review
Review book
Invite someone to review
Bookmark
Cite as...
There is no author summary for this book yet. Authors can add summaries to their books on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
ScienceOpen Clinical Case Reports Collection
Author and book information
Book
ISBN (Print):
978-3-662-50350-8
ISBN (Electronic):
978-3-662-50351-5
Publication date (Print):
2016
DOI:
10.1007/978-3-662-50351-5
SO-VID:
58c39f01-bbf5-4f1e-9ae2-cd1c10d94111
History
Data availability:
Comments
Comment on this book
Sign in to comment
Book chapters
pp. 3
Arzneiverordnungen 2015 im Überblick
pp. 29
Zulassungsverfahren für neue Arzneimittel in Europa
pp. 49
Neue Arzneimittel 2015
pp. 135
GKV-Arzneimittelmarkt 2015: Trends und Marktsegmente
pp. 159
Ergebnisse des AMNOG-Erstattungsbetragsverfahrens
pp. 181
Rabattverträge
pp. 193
Europäischer Preisvergleich für patentgeschützte Arzneimittel
pp. 209
Hemmstoffe des Renin-Angiotensin-Systems
pp. 237
Analgetika
pp. 251
Antiallergika
pp. 265
Antianämika
pp. 273
Antibiotika und Chemotherapeutika
pp. 293
Antidementiva
pp. 301
Antidiabetika
pp. 319
Antiemetika und Antivertiginosa
pp. 323
Antiepileptika
pp. 335
Antihypertonika
pp. 351
Antithrombotika und Antihämorrhagika
pp. 369
Antirheumatika und Antiphlogistika
pp. 381
Antitussiva und Expektorantien
pp. 391
Betarezeptorenblocker
pp. 399
Bronchospasmolytika und Antiasthmatika
pp. 413
Calciumantagonisten
pp. 421
Corticosteroide
pp. 427
Dermatika
pp. 471
Diuretika
pp. 481
Gichtmittel
pp. 485
Herztherapeutika
pp. 499
Hypnotika und Sedativa
pp. 509
Hypophysen- und Hypothalamushormone
pp. 517
Immuntherapeutika
pp. 523
Lipidsenkende Mittel
pp. 531
Magen-Darm-Mittel und Lebertherapeutika
pp. 553
Migränemittel
pp. 561
Mittel zur Behandlung der multiplen Sklerose
pp. 577
Mund- und Rachentherapeutika
pp. 583
Onkologika
pp. 621
Ophthalmika
pp. 643
Osteoporosemittel
pp. 653
Parkinsonmittel
pp. 663
Psychopharmaka
pp. 691
Rhinologika und Otologika
pp. 699
Schilddrüsentherapeutika
pp. 705
Sexualhormone
pp. 719
Urologika
pp. 729
Vitamine und Mineralstoffpräparate
pp. 739
Zahnärztliche Arzneiverordnungen
pp. 753
Überblick über die Arzneiverordnungen nach Arztgruppen
pp. 763
Arzneimittelverordnungen nach Alter und Geschlecht
pp. 775
Arzneimittelverordnungen nach Regionen
pp. 785
Ergänzende statistische Übersicht
Similar content
1,671
Arzneiverordnungs-Report 2022
Authors:
Arzneiverordnungs-Report 2017. Aktuelle Daten, Kosten, Trends und Kommentare
Authors:
Arzneiverordnungs-Report 1994
Authors:
U. SCHWABE
,
D Paffrath
See all similar
Cited by
1
Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022
Authors:
Lilly Josephine Bindel
,
Roland Seifert
See all cited by